SynthesisRheumatology international2016
What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review.
Synthesis in Rheumatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- [Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].Zeitschrift fur Rheumatologie · 2020Pooled it
- Clinical Association of Pan-Immune-Inflammation Value with MEFV Mutation Burden and Amyloidosis in Adults with Familial Mediterranean Fever: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Evaluation of renal elasticity by shear wave elastography in children with Familial Mediterranean Fever.Pediatric nephrology (Berlin, Germany) · 2025Article
- Pan-Immune-Inflammation Value Could Be a New Marker to Predict Amyloidosis and Disease Severity in Familial Mediterranean Fever.Diagnostics (Basel, Switzerland) · 2024Article
- Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience.Pediatric rheumatology online journal · 2023Article
- Treat-to-target strategies for the management of familial Mediterranean Fever in children.Pediatric rheumatology online journal · 2023Article
- Importance of hematological markers in familial Mediterranean fever in terms of disease severity and amyloidosis.Rheumatology international · 2023Article
- Assessment of Serum Resistin and Plasma Calprotectin Levels as Biomarkers of Inflammation in Patients with Familial Mediterranean Fever Disease.Mediterranean journal of rheumatology · 2022Article
- The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.International journal of molecular sciences · 2022Review
- Adherence to best practice consensus guidelines for familial Mediterranean fever: a modified Delphi study among paediatric rheumatologists in Turkey.Rheumatology international · 2022Observational
- Evaluation of E148Q and Concomitant AA Amyloidosis in Patients with Familial Mediterranean Fever.Journal of clinical medicine · 2021Article
- Evaluation of serum CXC chemokine ligand 16 (CXCL16) as a novel inflammatory bio- marker or familial Mediterranean fever diseaseTurkish journal of medical sciences · 2021Article
- Using urinary neutrophile gelatinase-associated lipocalin for prognosticate renal dysfunction in children with familial Mediterranean fever the study design: a pilot study.Advances in rheumatology (London, England) · 2021Article
- The role of azurocidin in patients with familial Mediterranean fever and AA amyloidosis and its association with cardiovascular risk factors.International urology and nephrology · 2021Article
- Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?Frontiers in pediatrics · 2021Article
- Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis.Scientific reports · 2020Article
- Spectrum of Genetic Autoinflammatory Diseases Presenting with Cutaneous Symptoms.Acta dermato-venereologica · 2020Review
- Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections.Clinical rheumatology · 2020Article
- [Evidence-based treatment recommendations for familial Mediterranean fever : A joint statement by the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].Zeitschrift fur Rheumatologie · 2019Review
- Long-term follow-up of paediatric MEFV carriers.Clinical rheumatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most dreaded complication of familial Mediterranean fever (FMF) is amyloidosis; controversy exists as to what acute phase reactant (APR) should be monitored in these patients. To analyze the best acute phase reactant for FMF follow-up to help guide physicians to decide on what APR parameter to use, we also attempted to define the best APR in predicting the complications of FMF, specifically the development of amyloidosis. Systematic review based on a sensitive search to capture studies that: (1) included FMF patients; (2) measured serum amyloid A (SAA), CRP (C-reactive protein), proteinuria, or ESR (erythrocyte sedimentation rate); (3) amyloidosis were the outcome measure; (4) sensitivity, specificity, predictive value, and other performance parameters could be calculated; and (5) had a longitudinal design. Of 1905 captured items, 26 were selected for detailed review, of which only two finally met the criteria, and the quality was only moderate; the articles did not analyzed the performance by means of sensitivity and specificity to predict, or even detect, amyloidosis, and thus had to be calculated based on text. The 26 screened studies were very heterogeneous in designs, parameters measured, and results, despite being set from research questions similar to ours. They were mainly descriptive, and it was very difficult to interpret the true performance of the tests. The correlation between the various APR is low. The evidence supporting the monitoring of FMF with any APR over the others is limited. Well designed longitudinal studies with a mixture of outcomes should be undertaken. Until them, recommending an APR over other would be based on expert opinion and indirect evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.